

*Prescription Drug Copays and Their Effect
on Vulnerable Populations*

This supplement to *The American Journal of Managed Care* is based on a closed-panel round-table meeting held in Philadelphia, Pennsylvania, on June 13, 2006, in which 5 experts in various fields discussed prescription drug copays and their effect on vulnerable populations.

Faculty

Michael E. Chernew, PhD

Professor of Healthcare Policy
Harvard Medical School
Boston, Massachusetts

William Fleming, PharmD

Vice President, Pharmacy and
Clinical Integration
Humana, Inc
Louisville, Kentucky

John J. Mahoney, MD

Corporate Medical Director
Pitney Bowes
Stamford, Connecticut

David Nash, MD, MBA

Dr. Raymond C. and Doris N. Grandon Professor
of Health Policy
Chairman, Department of Health Policy
Jefferson Medical College
Philadelphia, Pennsylvania

Richard C. Surles, PhD

Executive Vice President
Comprehensive NeuroScience, Inc
Pennington, New Jersey

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Michael E. Chernew, PhD**

Consultant to:

Active Health Management

Grant/research support from:

GlaxoSmithKline

Pfizer

■ **Richard C. Surles, PhD**

Honorarium:

Eli Lilly

The following participants have declared no financial affiliations with corporate organizations:

■ **William Fleming, PharmD**

■ **John J. Mahoney, MD**

■ **David Nash, MD, MBA**

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

*Prescription Drug Copays and Their Effect
on Vulnerable Populations*

This program is supported by an educational grant from **Eli Lilly**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.